ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published online before print August 6, 2008, 10.1183/09031936.00020608
Eur Respir J 2008; 32:1283-1288
Copyright ©ERS Journals Ltd 2008
doi: 10.1183/09031936.00020608

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
32/5/1283    most recent
09031936.00020608v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barbier, M.
Right arrow Articles by Albertí, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barbier, M.
Right arrow Articles by Albertí, S.

Fluticasone propionate reduces bacterial airway epithelial invasion

M. Barbier1, A. Agustí2,3,4 and S. Albertí1

1 University Institute of Health Sciences Research (IUNICS), University of the Balearic Islands, 2 Pneumology Dept, Son Dureta Hospital, 4 CIBER Enfermedades Respiratorias (CIBERES), Palma de Mallorca, and 3 The Caubet–Cimera Foundation, Buñola, Spain.

CORRESPONDENCE: S. Albertí, Institut Universitari dInvestigacions en Ciències de la Salut (IUNICS), Universitat de les Illes Balears (UIB), Palma de Mallorca, Spain, Fax: 34 971173184. E-mail: sebastian.alberti{at}uib.es

Keywords: Airway epithelial cells, bacterial infections, chronic obstructive pulmonary disease, fluticasone

Received: February 11, 2008
Accepted July 14, 2008

Fluticasone propionate reduces the frequency and severity of the episodes of exacerbation of chronic obstructive pulmonary disease (COPD). Streptococcus pneumoniae and Haemophilus influenzae are frequently isolated in these episodes. Both express phosphorylcholine, an epitope that mediates their interaction with airway epithelial cells via the platelet-activating factor receptor (PAFR).

The present work studies the effects of fluticasone propionate on the expression of PAFR on human airway epithelial cells, the invasion of these cells by S. pneumoniae and H. influenzae, and the course of pneumococcal infection in vivo. The following were used in the experiments: S. pneumoniae and H. influenzae isolated from patients with COPD, cell cultures of type II pneumocytes and bronchoepithelial cells, and a mouse model of lung infection.

Fluticasone propionate was found to reduce PAFR expression on the surface of the two cells types studied. All S. pneumoniae and H. influenzae isolates expressed phosphorylcholine. Treatment of both cells lines with fluticasone propionate reduced invasion of both microorganisms and reduced the bacterial load of mice infected with S. pneumoniae.

Fluticasone propionate reduces the invasion of airway epithelial cells by Streptococcus pneumoniae and Haemophilus influenzae through its effect on platelet-activating factor receptor. These results may help explain the beneficial effects of fluticasone propionate on chronic obstructive pulmonary disease exacerbations.




This article has been cited by other articles:


Home page
 QJMHome page
A. Singanayagam, J.D. Chalmers, and A.T. Hill
Inhaled corticosteroids and risk of pneumonia: evidence for and against the proposed association
QJM, March 15, 2010; (2010) hcq023v1.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the European Respiratory Society.